Purtell L, Viardot A, Sze L, Loughnan G, Steinbeck K, Sainsbury A, et al
Abbreviations CVE: Cardiovascular event EHR: Electronic health record GLP-1RA: Glucagon-like peptide-1 receptor agonist MACE: Major adverse cardiovascular events NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis PCI: Percutaneous coronary intervention PSM: Propensity score matching SGLT2: Sodiumglucose cotransporter 2 SMD: Standardised mean difference TG: Triacylglycerol References Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes
They are all small molecules which act as reversible competitive inhibitors of the catalytic activity of DPP-4 and, when used at the appropriate therapeutic dose, are associated with at least 70% inhibition of plasma DPP-4 activity ( in vivo is likely to be higher, due to dilution of the inhibitor in the ex vivo assay)
Exercise should not be considered a substitute for medication, she said
An innovative oral form of GLP-1 receptor agonist was assessed in The Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 trial
The popularity of these GLP-1 drugs have led to companies creating unapproved versions that are sold online
